title: Sustained anabolic effects of long-term androgen administration in men with AIDS wasting.
abstract: Fifty-one human immunodeficiency virus-positive men with hypogonadism and wasting were randomized to receive testosterone enanthate, 300 mg i.m. every 3 weeks, or placebo for 6 months, followed by open-label testosterone administration for 6 months. Subjects initially randomized to placebo gained lean body mass (LBM) only after crossover to testosterone administration (mean change +/- standard error of the mean, -0.6 +/- 0.7 kg [months 0-6] vs. 1.9 +/- 0.7 kg [months 6-12]; P = .03). In contrast, subjects initially randomized to testosterone continued to gain LBM during open-label administration (2.0 +/- 0.7 kg [months 0-6] vs. 1.6 +/- 0.6 kg [months 6-12]; P = .62) and had gained more LBM at 1 year than did subjects receiving testosterone for only the final 6 months of the study (3.7 +/- 0.8 kg vs. 1.0 +/- 1.0 kg; P = .05). Testosterone administration results in sustained increases in LBM during 1 year of therapy in hypogonadal men with AIDS wasting.
authors: Infectious Disease Unit, and General Clinical Research Center, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA. sgrinspoon@partners.org
authors: S
authors: S
authors: Grinspoon
authors: C
authors: C
authors: Corcoran
authors: E
authors: E
authors: Anderson
authors: J
authors: J
authors: Hubbard
authors: T
authors: T
authors: Stanley
authors: N
authors: N
authors: Basgoz
authors: A
authors: A
authors: Klibanski
mesh_terms: D018592:Cross-Over Studies; D019247:HIV Wasting Syndrome / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007006:Hypogonadism / Q000150:complications / Q000188:drug therapy; D008297:Male; D011788:Quality of Life; D013739:Testosterone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors; D015430:Weight Gain
chemical_list: D013739:Testosterone; C004648:testosterone enanthate